2013 - 3 Issue

Original article

Glaucoma Therapy – Current Overview of Data and Information

Petr Výborný
Silvia Sičáková – Pavla Dohnalová – Marina Feřtek – Tomáš Doležal

Full Text links

DOI:

Published in Czech and Slovak Ophtalmology: 2013 - 3

Published on website: 21.05.2013

Keywords: glaucoma, prescription, surgical treatment, treatment costs, legal issues

Summary

The authors submit the overview of the actual situation in the glaucoma therapy. They follow up the trends in antiglaucomatic treatment in the last period including financial aspects of medicament and surgical treatment. Attention is paid especially to medicaments management, actual overview of available antiglaucomatic drugs, function and position of generic drugs and differences among them, the daily dose of benzalconium chloride in glaucoma treatment, actual average of patients’ supplementary payments at the drug purchase in the pharmacy, surgical treatment costs and legal issues. Pharmacologist’s viewpoints and the Czech State Drug Control Authority (SÚKL) opinions complete the professional’s point of the view and facilitate his/her complete orientation in glaucoma therapy issues.

References

  1. Daull, P, Garriguie, J.S.: Preservative- -free cationic nano emulsion of latanoprost. Ophthalmology Times Europe, Jan/Feb 2013: 8–10.
  2. Doležal, T.: Od molekuly k dlouhodobé spokojenosti pacienta. Farmakoterapie, 2; 6, 2012: 4–6.
  3. Herndon, L.W, Asrani, S.G., Williams, G. H. et al.: Paradoxial intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. Arch Ophthalmol, 120; 2002: 847–849.
  4. IMS Health – analytická společnost, Praha, Dataview 2010–2012.
  5. Liang, H., Baudoin, P., Daull, P. et al: In vitro and in vivo evaluation of preservativefree cationic emulsion of latanoprost in cornal wound healing. Cornea, 31; 2012: 1319–1329.
  6. Prokeš, M.: Prekripční a indikační omezení pro léky v České republice. Farmakoekonomika, 6; 2012: 2–6.
  7. Výborný, P., Sejčková, L.: Antiglaukomatika – obsah konzervaãních látek a spolupráce pacienta v léčebném režimu. Čes a Slov Oftal, 62; 2006: 270–274.
  8. Výborný, P., Dohnalová, P., Sičáková, S.: Antiglaukomatika v šíslech a tabulkách – trendy v preskripci. In Trendy soudobé oftalmologie, svazek 8, Ed. Rozsíval P., Praha, Galén 2012, 247–255.
  9. Conclusion At present we are witnesses to substantial progress in the diagnosis and therapy of glaucoma. Patient awareness of this disease has fundamentally improved also thanks to the media, in particular the internet. A very varied assortment of pharmaceuticals is available for conservative therapy, as well as several new intervention procedures. In deciding on treatment, doctors are governed not only by the principles of good clinical practice and by their knowledge, but must also bear in mind a range of further related factors. The patient and doctor are within a specific environment in which both economic and legislative costs exert a considerable influence. For better orientation within this issue, an overview of the data and information relating to glaucoma therapy has been created in co-operation with pharmacologists and the state authority (SÚKL). Table 14. Report of suspect adverse drug reaction